Key Considerations When Selecting EGFR Inhibitor Treatments in NSCLC - Episode 8
The Future of Biomarkers in EGFR-Mutant NSCLC: Sequencing Strategies and Optimizing Patient Time on Treatment
Panelists discuss how optimizing treatment duration, using local therapy for oligometastatic disease, and understanding the limitations of current biomarkers are important considerations in developing effective sequencing strategies for EGFR-mutant lung cancer.
Video Player is loading.
Video content above is prompted by the following:
Optimizing Treatment Sequencing
Key Themes:
- Local Therapy: Role of stereotactic body radiation therapy (SBRT) for oligoprogressive disease
- Maintenance Strategies: Questions about optimal duration of chemotherapy maintenance and amivantamab treatment
- Treatment Sequencing: Impact of first-line therapy selection on subsequent options
Notable Insights:
- Dr Dietrich: Supports local treatment for oligoprogressive disease, stating “depending on the patient in my practice, up to 6 sites are reasonable” for SBRT treatment. He believes “the impact of amivantamab or chemotherapy respectively is best when EGFR disease is sensitized by a third-generation EGFR [tyrosine kinase inhibitor] backbone.”
- Dr Piotrowska: Expressed concern about biomarker-directed therapy, noting “we’ve taken a step back from that” with combination approaches where “we really don’t know which patients are likely to benefit from each.” She emphasized the need for better biomarkers to guide both frontline and later-line therapy selection.
Related Content:
